HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Specific targeting of breast tumor by octreotide-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 3.0-Tesla magnetic resonance scanner.

AbstractBACKGROUND:
Targeted magnetic resonance contrast agents have enabled the imaging of biological processes in vivo, and current insights have opened up new perspectives for the monitoring and diagnosis of many diseases.
PURPOSE:
To develop a contrast agent for targeting somatostatin receptors (SSTRs) expressed on breast cancer cells, and to evaluate the detection capabilities of a molecular probe using magnetic resonance (MR) imaging in an in vivo mouse model of breast carcinoma.
MATERIAL AND METHODS:
Octreotide (OCT) was conjugated with polyethylene glycol-coated ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles by an ethyl-3-(dimethylaminopropyl) carbodiimide (EDC)-mediated reaction. Prussian blue staining for intracellular iron, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and cellular MR imaging in vitro were performed on labeled MCF-7 breast cancer cells. Twenty-four mice bearing tumors were divided into two groups: 1) study group with injection of OCT-USPIOs (n=12); 2) control group with injection of USPIOs (n=12). Tumors were monitored in vivo using a 3.0-Tesla MR scanner before and after injection of contrast agents, and the findings were correlated with the histopathological findings.
RESULTS:
OCT-USPIOs were shown to specifically bind to MCF-7 cells and did not affect proliferation and viability of the cells labeled. T(2) value of the cells labeled with OCT-USPIOs in vitro was 56.465+/-13.147 ms, while those of the cells cultured with USPIOs and gelatin/phosphate-buffered saline (PBS) gel alone were 75.435+/-16.171 ms and 85.950+/-22.352 ms, respectively (P<0.05). Signal intensity of the tumor gradually decreased, and its T(2) value reached a minimum of approximately 24.49% 6 hours after injection of OCT-USPIOs in vivo, compared to a minimum of 21.89% after 2 hours in the control group. Iron depositions were visualized as blue particles in tumor 6 hours after injection of OCT-USPIOs, while no blue particles were observed in the control group.
CONCLUSION:
SSTR expression in vitro and in vivo can be selectively and directly imaged with an MR molecular probe. OCT-conjugated PEG-coated USPIO is potentially suitable to be used as a magnetic resonance contrast agent for MR imaging in vivo and increases the sensitivity for the early detection of breast carcinoma.
AuthorsXubin Li, Xiangke Du, Tianlong Huo, Xia Liu, Sen Zhang, Fei Yuan
JournalActa radiologica (Stockholm, Sweden : 1987) (Acta Radiol) Vol. 50 Issue 6 Pg. 583-94 (Jul 2009) ISSN: 1600-0455 [Electronic] England
PMID19449236 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Contrast Media
  • Dextrans
  • Magnetite Nanoparticles
  • Oxides
  • ferumoxtran-10
  • Iron
  • Octreotide
  • Ferrosoferric Oxide
Topics
  • Animals
  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms (diagnosis, pathology)
  • Contrast Media
  • Dextrans
  • Disease Models, Animal
  • Female
  • Ferrosoferric Oxide
  • Humans
  • Image Enhancement (methods)
  • Iron
  • Magnetic Resonance Imaging (methods)
  • Magnetite Nanoparticles
  • Mice
  • Mice, Nude
  • Octreotide
  • Oxides
  • Polymerase Chain Reaction (methods)
  • Sensitivity and Specificity
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: